Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The study consists of three parts
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants at the time of signing the Informed Consent Form (ICF) are at least 18 years old or are of the legal age of consent in the jurisdiction in which the study is taking place.
Participants who have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG, and measurable disease.
PART 1: Participants who have received at least 3 prior lines of anti-myeloma treatments, and have already received an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 mAb (unless contraindicated or unavailable). Lines of therapy are defined by consensus panel of the International Myeloma Workshop.
PART 2: Participants who meet all of the following:
Have undergone Autologous stem cell transplant (ASCT) or are considered transplant ineligible
Have been previously treated with at least ONE prior line of MM therapy
Have documented disease progression during or after their most recent therapy
PART 3: Participants who meet both of the following:
NDMM with a requirement for treatment as documented per IMWG criteria
Not considered a candidate for high dose chemotherapy with ASCT due to:
Participants capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
124 participants in 3 patient groups
Loading...
Central trial contact
EU GSK Clinical Trials Call Center; US GSK Clinical Trials Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal